Compare IMVT & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | FCN |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.1B |
| IPO Year | N/A | 1996 |
| Metric | IMVT | FCN |
|---|---|---|
| Price | $26.19 | $175.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | $27.75 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.9M | 341.7K |
| Earning Date | 02-05-2026 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.77 |
| Revenue | N/A | ★ $3,693,035,000.00 |
| Revenue This Year | N/A | $1.50 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.72 | $149.31 |
| 52 Week High | $27.69 | $204.69 |
| Indicator | IMVT | FCN |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 61.48 |
| Support Level | $26.35 | $173.19 |
| Resistance Level | $27.64 | $179.83 |
| Average True Range (ATR) | 1.39 | 3.68 |
| MACD | 0.06 | 0.51 |
| Stochastic Oscillator | 71.64 | 72.02 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.